Eli Lilly (NYSE:LLY) Beats Q1 Sales Targets
Global pharmaceutical company Eli Lilly (NYSE:LLY) reported Q1 CY2025 results exceeding the market's revenue expectations , with sales up 45.2% year on year to $12.73 billion. The company expects the full year's revenue to be around $59.5 billion, close to analysts' estimates. Its non-GAAP profit of $3.34 per share was 3.4% below analysts' consensus estimates.
Is now the time to buy Eli Lilly? Find out in our full research report.
Revenue: $12.73 billion vs analyst estimates of $12.62 billion (45.2% year-on-year growth, 0.9% beat)
Adjusted EPS: $3.34 vs analyst expectations of $3.46 (3.4% miss)
The company reconfirmed its revenue guidance for the full year of $59.5 billion at the midpoint
Management lowered its full-year Adjusted EPS guidance to $21.53 at the midpoint, a 7.4% decrease
Operating Margin: 29%, in line with the same quarter last year
Market Capitalization: $807.2 billion
"Lilly had a solid start to the year, with 45% year-over-year revenue growth driven by strong sales of Mounjaro and Zepbound," said David A. Ricks, Lilly chair and CEO.
Founded in 1876 by a Civil War veteran and pharmacist who was frustrated with the poor quality of medicines available at the time, Eli Lilly (NYSE:LLY) discovers, develops, and manufactures pharmaceutical products for conditions including diabetes, obesity, cancer, immunological disorders, and neurological diseases.
Examining a company's long-term performance can provide clues about its quality. Any business can put up a good quarter or two, but many enduring ones grow for years. Over the last five years, Eli Lilly grew its sales at a solid 16.2% compounded annual growth rate. Its growth surpassed the average healthcare company and shows its offerings resonate with customers, a great starting point for our analysis.
Long-term growth is the most important, but within healthcare, a half-decade historical view may miss new innovations or demand cycles. Eli Lilly's annualized revenue growth of 33% over the last two years is above its five-year trend, suggesting its demand was strong and recently accelerated.
This quarter, Eli Lilly reported magnificent year-on-year revenue growth of 45.2%, and its $12.73 billion of revenue beat Wall Street's estimates by 0.9%.
Looking ahead, sell-side analysts expect revenue to grow 28.5% over the next 12 months, a deceleration versus the last two years. Still, this projection is eye-popping given its scale and implies the market is forecasting success for its products and services.
Software is eating the world and there is virtually no industry left that has been untouched by it. That drives increasing demand for tools helping software developers do their jobs, whether it be monitoring critical cloud infrastructure, integrating audio and video functionality, or ensuring smooth content streaming. Click here to access a free report on our 3 favorite stocks to play this generational megatrend.
Operating margin is a key measure of profitability. Think of it as net income - the bottom line - excluding the impact of taxes and interest on debt, which are less connected to business fundamentals.
Eli Lilly has been an efficient company over the last five years. It was one of the more profitable businesses in the healthcare sector, boasting an average operating margin of 24.5%.
Looking at the trend in its profitability, Eli Lilly's operating margin rose by 6.7 percentage points over the last five years, as its sales growth gave it operating leverage. The company's two-year trajectory shows its performance was mostly driven by its recent improvements. These data points are very encouraging and shows momentum is on its side.
This quarter, Eli Lilly generated an operating profit margin of 29%, in line with the same quarter last year. This indicates the company's overall cost structure has been relatively stable.
Revenue trends explain a company's historical growth, but the long-term change in earnings per share (EPS) points to the profitability of that growth – for example, a company could inflate its sales through excessive spending on advertising and promotions.
Eli Lilly's EPS grew at an astounding 17.6% compounded annual growth rate over the last five years, higher than its 16.2% annualized revenue growth. This tells us the company became more profitable on a per-share basis as it expanded.
Diving into Eli Lilly's quality of earnings can give us a better understanding of its performance. As we mentioned earlier, Eli Lilly's operating margin was flat this quarter but expanded by 6.7 percentage points over the last five years. On top of that, its share count shrank by 1.2%. These are positive signs for shareholders because improving profitability and share buybacks turbocharge EPS growth relative to revenue growth.
In Q1, Eli Lilly reported EPS at $3.34, up from $2.58 in the same quarter last year. Despite growing year on year, this print missed analysts' estimates, but we care more about long-term EPS growth than short-term movements. Over the next 12 months, Wall Street expects Eli Lilly's full-year EPS of $13.76 to grow 84.4%.
It was good to see Eli Lilly narrowly top analysts' revenue expectations this quarter. On the other hand, its EPS in the quarter missed on lower-than-expected profitability and full-year EPS guidance also missed significantly. Overall, this was a softer quarter. The stock traded down 3.9% to $860.72 immediately after reporting.
Eli Lilly underperformed this quarter, but does that create an opportunity to invest right now? The latest quarter does matter, but not nearly as much as longer-term fundamentals and valuation, when deciding if the stock is a buy. We cover that in our actionable full research report which you can read here, it's free.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Xi Has 'Bowed To Reality,' Says China Analyst, Urges More Engagement Between Leaders To Resolve Trade Issues: 'No Substitute For Direct Negotiations With Trump'
Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below. As U.S. President Donald Trump and Chinese President Xi Jinping break the ice with a phone call after months of silence, analysts weigh in on what's in store for the U.S.-China trade. What Happened: The U.S. and China have been at odds over trade for a considerable period. The call signifies some advancement in establishing ground rules for a potential meeting. Jeremy Chan, Senior China Analyst at the Eurasia Group consultancy, stated that this communication suggests a level of respect from President Trump towards President Xi, reported The South China Morning Post. Trending: Start investing with eToro's CopyTrader — . However, analysts have noted that more than optimistic statements are required to resolve the deeply rooted trade differences between the two nations. Chan further noted that Xi typically consents to meetings with foreign leaders only after substantial groundwork has been laid through lower-level diplomatic efforts. "Xi has bowed to reality, like so many other foreign leaders before him, that there is no substitute for direct negotiations with Trump," stated Chan, who is also a former U.S. diplomat. On the other hand, ASPI's Wendy Cutler highlighted the complexity of the upcoming trade talks and the challenges. "The likelihood of further misunderstandings, coupled with a fundamental lack of trust, will present enormous challenges for the negotiators as they try to hammer out a deal," cautioned It Matters: This phone call comes in the wake of escalating trade tensions between the two countries. On Thursday, U.S. stocks dipped following reports of a phone call between Presidents Donald Trump and Xi Jinping, signaling a possible thaw in China trade tensions. The outreach was said to have come from the U.S. side, as per CNBC, citing Chinese state media. Earlier in May, President Trump had expressed his willingness to travel to China to meet with President Xi Jinping, emphasizing the importance of the U.S.-China relationship. In early May, the South China Morning Post reported that the U.S. and China are struggling to resume trade talks. China suggested using special envoys, but the U.S. prefers direct talks between Trump and Xi—a move China considers 'risky and uncertain.' This latest phone call could be seen as a step towards that potential meeting, and a move towards resolving the trade disputes. Baidu Inc (NASDAQ:BIDU) and Alibaba Group Holding Ltd – ADR (NYSE:BABA) climbed 1.13% and 0.43%, respectively, on Thursday. Meanwhile, Inc. (NASDAQ:JD) declined 0.72% Read Next: Nancy Pelosi Invested $5 Million In An AI Company Last Year — Here's How You Can Invest In Multiple Pre-IPO AI Startups With Just $1,000. Invest Where It Hurts — And Help Millions Heal: Invest in Cytonics and help disrupt a $390B Big Pharma stronghold. Image via Shutterstock This article Xi Has 'Bowed To Reality,' Says China Analyst, Urges More Engagement Between Leaders To Resolve Trade Issues: 'No Substitute For Direct Negotiations With Trump' originally appeared on
Yahoo
an hour ago
- Yahoo
Is American Express Worth Buying Right Now?
American Express is a well-run financial giant. The company's target audience is highly resilient to economic hardship. Is the strength of this business model enough to make it a buy? 10 stocks we like better than American Express › American Express (NYSE: AXP) is one of the stocks owned by Warren Buffett within Berkshire Hathaway's stock portfolio. That fact alone is enough to get some investors to buy the stock. However, you really need to consider other factors, like the business behind the stock, as well as its price tag. Here's a look at whether American Express is worth buying right now. American Express is a financial giant, acting largely as a payment processor. The company's logo adorns credit cards that get used in retail establishments and online. Each transaction generates fee income for American Express. It issues its own cards, too, so it generates card/membership fees directly from customers there, as well. One differentiation between American Express and its peers is that Amex, as it is often called, focuses on more affluent customers. Wealthier consumers tend to be more resilient during economic downturns. Basically, they have the money to keep spending even as less affluent consumers hunker down. That means that Amex's business will usually perform relatively well during recessions and other periods of economic uncertainty. So far, 2025 has been filled with uncertainty. From tariff fights to stock market corrections, the news has been filled with negative headlines. In fact, American Express' stock price fell along with the S&P 500 (SNPINDEX: ^GSPC) earlier in the year. And it has recovered along with the index as well, as investors regained confidence. What's notable, however, is that American Express' price moves have been more dramatic than the market's moves. That's an interesting sign, since it could mean that Amex's stock has more recovery potential ahead of it. Given the strength of its business model, that isn't an unreasonable assessment. However, there's also a negative way to view the price swing. It could very well be that investors got overly enthusiastic about the business and bid the price up to unrealistic levels earlier in the year. And the return toward those levels just indicates that investors are, again, being overzealous with their expectations. A look at traditional valuation metrics, perhaps unfortunately, suggests the second explanation is the more likely one. American Express' price-to-sales ratio is currently around 3.1, compared to a five-year average of 2.6. The price-to-earnings (P/E) ratio is currently about 20.5, versus a longer-term average of just under 19. And the price-to-book value ratio is 6.6 today, compared to a five-year average of roughly 5. All three metrics suggest that American Express is expensive today. And they are buttressed by a nontraditional valuation tool: dividend yield, which falls as share price rises. American Express' dividend yield is about 1.1% today. Not only is that less than the already miserly 1.3% yield you could collect from the S&P 500 index, but it is also near the lowest levels of the past decade. Again, the direction is pretty clear: Amex looks expensive. There's a reason Warren Buffett owns American Express. It is a well-run business with some clear advantages over its peers. Buffett didn't just buy Amex -- he's owned it for many years. And sticking with a good company is part of Buffett's investment approach. However, Buffett's mentor, Benjamin Graham, made an important observation that investors looking at American Express today should heed: Even great companies can be bad investments if you pay too much for them. And it looks like American Express is too expensive right now. Before you buy stock in American Express, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and American Express wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $674,395!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $858,011!* Now, it's worth noting Stock Advisor's total average return is 997% — a market-crushing outperformance compared to 172% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 2, 2025 American Express is an advertising partner of Motley Fool Money. Reuben Gregg Brewer has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Berkshire Hathaway. The Motley Fool has a disclosure policy. Is American Express Worth Buying Right Now? was originally published by The Motley Fool
Business Upturn
an hour ago
- Business Upturn
Infosys inaugurates new Development Center at GIFT City to boost BFSI Tech services
Infosys (NSE, BSE, NYSE: INFY), a global leader in digital services and consulting, has inaugurated its new Development Center (DC) at Gujarat International Finance Tec-City (GIFT City), Gandhinagar. The newly launched facility is designed to support over 1,000 employees operating in a hybrid work model. The center will serve as a strategic TechFin hub, focusing on delivering advanced digital solutions to global Banking, Financial Services, and Insurance (BFSI) clients. Key service areas include digital banking, regulatory compliance, capital markets, trade finance, cards and payments, and risk management. Infosys will harness cutting-edge technologies such as Artificial Intelligence (AI), Generative AI (Gen AI), cloud, APIs, blockchain, and cybersecurity to provide seamless cross-border digital services and enhance client engagement. The Development Center was inaugurated by the Hon'ble Chief Minister of Gujarat, Shri Bhupendrabhai Patel. Infosys CFO Mr. Jayesh Sanghrajka, Senior Vice Presidents Mr. Niladri Prasad Mishra and Mr. Rajneesh Malviya, along with senior government officials, were present at the event. Aligned with Infosys' ESG (Environmental, Social, and Governance) goals, the facility integrates sustainable design features including energy efficiency, water conservation, and smart operational systems. The workplace also supports collaboration, productivity, and innovation through a future-ready hybrid office model. This initiative reinforces Infosys' commitment to strengthening India's role as a global financial technology hub and driving innovation in the BFSI sector. Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
